Insider trade

Officer sold ~$282K of CYTK shares in the open market

Traded Jul 21, 2026 · Filed Jul 23, 2026

Why it stands out

Cytokinetics's Research & Development sold $282K of Cytokinetics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$282,065

Shares × reported transaction price

Timing vs results

77 days after results of May 5, 2026, 16 days before results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−4.5%	+1.1%	−5.6%
30 days	−4.5%	+3.3%	−7.8%

Past results only. Not a forecast.

Filed 7w ago

Traded Aug 18 · filed the same day

Derivative exercise or conversion — not an open-market buy.

Automatic saleFiled 7w ago

Filed 7w ago

Traded Aug 18 · filed the same day

Derivative exercise or conversion — not an open-market buy.